Novavax stock surge after its potential vaccine proved to be more than 89% effective against COVID-19
The drop was mostly caused by the new data released by Johnson & Johnson regarding the effectiveness of its COVID-19 vaccine. The Phase III trials showed that the vaccine was 72% effective in the US, 66% in Latin America, and 57% in South Africa, after weeks of late-stage trials. According to #JNJ, the vaccine’s overall effectiveness is 66%.
Following the news, JNJ stock price slipped more than 4%.
On the other hand, Novavax – another biotech company working on a COVID-19 vaccine revealed that its candidate was more than 89% effective. The information is based on the Phase III clinical trial conducted in the UK on 15,000 participants.
According to Novavax CEO, Stanley Erck, the company “has the potential to play an important role in solving this global public health crisis.”
After the news about Novavax hit the wires, its stock price gained roughly 23%.
Read here about how JNJ has performed in Q4 2020!
This information is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation or the particular needs of any recipient.
You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.
This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent.
Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of sc.capex.com